<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Sulfatides are sulfated <z:chebi fb="0" ids="24402">glycosphingolipids</z:chebi> expressed on the surface of erythrocytes, leukocytes, and platelets </plain></SENT>
<SENT sid="1" pm="."><plain>Sulfatides interact with several cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules involved in hemostasis </plain></SENT>
<SENT sid="2" pm="."><plain>Beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I is an anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding plasma protein, and the <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-bound form is the target for most anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies that are associated with <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo>, <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e>, and neurological symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we examined whether beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I forms a complex with sulfatides and thereby becomes a target for anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: Beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I binds to surface-bound sulfatides but not to other <z:chebi fb="0" ids="33563">glycolipids</z:chebi>, such as <z:chebi fb="7" ids="17761">ceramide</z:chebi>, cerebrosides, <z:chebi fb="0" ids="17636">sphingomyelin</z:chebi>, or <z:chebi fb="0" ids="28892">ganglioside</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>At a sulfatide coating density of 1 microg/well, beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I reaches half-maximal binding at 2.5 microg/mL, and the binding is saturated at 10 microg/mL </plain></SENT>
<SENT sid="6" pm="."><plain>The binding of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I also depends on the coating density of sulfatides in the well </plain></SENT>
<SENT sid="7" pm="."><plain>At a constant beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I concentration of 5 microg/mL, maximal binding of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I is observed at a coating density of 1 mug/well </plain></SENT>
<SENT sid="8" pm="."><plain>The serum from 14 patients with anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies, a subset of anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies, bound to sulfatide-bound beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I and previous absorption on <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>-coated surfaces decreased the immunoreactivity toward sulfatide-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I complex by &gt;50% in 12 of 14 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, immunoaffinity-purified anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies from 4 of 5 patients reacted with sulfatide-bound beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These results show that not only anionic <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, as commonly known, but also sulfatides are targets for most anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies </plain></SENT>
<SENT sid="11" pm="."><plain>We therefore postulate that interactions of these antibodies with sulfatides may contribute to some of the clinical symptoms of the anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome </plain></SENT>
</text></document>